DYF1 Stock Overview
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.43 |
| 52 Week High | US$14.01 |
| 52 Week Low | US$9.61 |
| Beta | 1.19 |
| 11 Month Change | 0.48% |
| 3 Month Change | -8.07% |
| 1 Year Change | -11.76% |
| 33 Year Change | 24.70% |
| 5 Year Change | 205.00% |
| Change since IPO | -65.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| DYF1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.1% | 0.6% | 0.09% |
| 1Y | -11.8% | -18.6% | 3.1% |
Return vs Industry: DYF1 exceeded the German Biotechs industry which returned -18.6% over the past year.
Return vs Market: DYF1 underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| DYF1 volatility | |
|---|---|
| DYF1 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DYF1 has not had significant price volatility in the past 3 months.
Volatility Over Time: DYF1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
| DYF1 fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | €8.61m |
| Revenue (TTM) | €220.45m |
159.4x
P/E Ratio6.2x
P/S RatioIs DYF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYF1 income statement (TTM) | |
|---|---|
| Revenue | US$236.15m |
| Cost of Revenue | US$98.47m |
| Gross Profit | US$137.68m |
| Other Expenses | US$128.46m |
| Earnings | US$9.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.07 |
| Gross Margin | 58.30% |
| Net Profit Margin | 3.91% |
| Debt/Equity Ratio | 36.1% |
How did DYF1 perform over the long term?
See historical performance and comparison